Approval to change the in-process coating weight acceptance criteria.  The device, as modified, will be marketed under the trade name taxus express2 paclitaxel-eluting coronary stent system and is indicated for improving luminal diameter for the treatment of de novo lesions <28 mm in length in native coronary arteries >=2.5 to <=3.75 mm in diameter.